Metronidazole in the treatment of metastatic brain tumors. Results of a controlled clinical trial

We measured the effect of the radiation enhancer metronidazole on patients with metastatic brain tumors undergoing radiation therapy (RT) in a randomized controlled study. Metronidazole was given in a dose of 6 g/m2 4 hr before each of the first 3 doses of RT to the whole-brain. A total of 3000 rad...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 1984-01, Vol.2 (2), p.105
Main Authors: Aiken, R, Leavengood, J M, Kim, J H, Deck, M D, Thaler, H T, Posner, J B
Format: Article
Language:English
Subjects:
Anticonvulsants - therapeutic use
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Clinical Trials as Topic
Dexamethasone - therapeutic use
Humans
Metronidazole - adverse effects
Metronidazole - antagonists & inhibitors
Metronidazole - therapeutic use
Tomography, X-Ray Computed
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We measured the effect of the radiation enhancer metronidazole on patients with metastatic brain tumors undergoing radiation therapy (RT) in a randomized controlled study. Metronidazole was given in a dose of 6 g/m2 4 hr before each of the first 3 doses of RT to the whole-brain. A total of 3000 rad was delivered in 6 doses. Patients were followed by serial neurological examinations and CT scans. The metronidazole group did not differ from the control group when measured in terms of survival, clinical improvement or improvement on CT scan, whether measured 2 months or 6 months following treatment. Nausea and vomiting was a significant side effect, preventing about 10% of patients from completing the treatment. Metronidazole appears to have no substantial radiation enhancing effect on metastatic brain tumors.
ISSN:0167-594X
1573-7373
DOI:10.1007/BF00177894